Case for caution, case for action

Bipolar Disorders

Volumn 5, Issue 6, 2003, Pages 434-435

  Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; FLUOXETINE; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; HUMAN; HYPOMANIA; MANIA; NOTE; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT;

AFFECT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SEIZURES;

EID: 0347286968     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-5618.2003.00076.x     Document Type: Note

References (11)

1. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003; 5: 421-433.
2. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
3. Hirschfeld RMA, Bowden CL, Gitlin MJ et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 59: 1-50.
4. Grunze H, Kasper S, Goodwin G et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of bipolar disorder, part I: treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115-124.
5. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am Psychiatry 2000; 157: 124-126.
6. Altshuler L, Suppes T, Black D et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252-1262.
7. Tohen MF, Bowden CL, Calabrese JR et al. Olanzapine versus Placebo for Relapse Prevention in Bipolar Disorder. American Psychiatric Association Meeting, San Francisco, May 17-22, 2003; NR 197.
8. Vieta E, Colom F, Martínez-Arán A et al. Reboxetine-induced hypomania. J Clin Psychiatry 2001; 62: 655-656.
9. Vieta E, Martínez-Arán A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood-stabilizers. J Clin Psychiatry 2002; 63: 508-512.
10. Vieta E. Do we need placebo control in maintenance studies in bipolar disorders?. Bipolar Disord 2002; 4 (Supp1 1): 61.
11. Tohen M, Vieta E, Calabrese JR et al. Efficacy of olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry, in press.